Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

57.30 +0.30 (+0.52%)
Streaming Delayed Price Updated: 10:57 AM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,882,615
Open 56.80
Bid (Size) 57.28 (300)
Ask (Size) 57.31 (200)
Prev. Close 57.00
Today's Range 56.45 - 57.42
52wk Range 42.52 - 62.89
Shares Outstanding 2,222,113,553
Dividend Yield 4.40%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗
This pair busts the myth of the sector being a desert for income investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property

Performance

YTD
+7.2%
+7.2%
1 Month
-6.5%
-6.5%
3 Month
+4.8%
+4.8%
6 Month
+27.4%
+27.4%
1 Year
-6.2%
-6.2%

More News

Read More
News headline image
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗
Via The Motley Fool
Topics Intellectual Property
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
Via MarketMinute
News headline image
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
From Bristol Myers Squibb
Via Business Wire
News headline image
1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Bristol‑Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
READYSTATE Dumps 361,000 Workiva Shares Worth $32 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
Via MarketMinute
Topics Earnings Economy Initial Public Offering
News headline image
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Question
Via StockStory
Topics Stocks
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Via MarketMinute
News headline image
3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗
Via The Motley Fool
News headline image
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Bristol Myers Squibb Stock Crushed it in February ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 57.30
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 03/24/26 10:57 AM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 127.32B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 127B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.